每次皮下注射艾氯胺酮治疗难治性抑郁症后的反应概率

IF 5.2 3区 医学 Q1 PSYCHIATRY
Victor Augusto Rodovalho Fava , Luciana Maria Sarin , Ana Cecília Lucchese , Lorena Del Sant , Eduardo Magalhães , Rodrigo Simonini Delfino , Marco Aurélio Tuena , Carolina Nakahira , Andrea Parolin Jackowski , Guilherme Abdo , Juliana Surjan , Matheus Steiglich , Matheus Ghossain Barbosa , José Alberto Del Porto , Acioly Luiz Tavares Lacerda , Hugo Cogo-Moreira
{"title":"每次皮下注射艾氯胺酮治疗难治性抑郁症后的反应概率","authors":"Victor Augusto Rodovalho Fava ,&nbsp;Luciana Maria Sarin ,&nbsp;Ana Cecília Lucchese ,&nbsp;Lorena Del Sant ,&nbsp;Eduardo Magalhães ,&nbsp;Rodrigo Simonini Delfino ,&nbsp;Marco Aurélio Tuena ,&nbsp;Carolina Nakahira ,&nbsp;Andrea Parolin Jackowski ,&nbsp;Guilherme Abdo ,&nbsp;Juliana Surjan ,&nbsp;Matheus Steiglich ,&nbsp;Matheus Ghossain Barbosa ,&nbsp;José Alberto Del Porto ,&nbsp;Acioly Luiz Tavares Lacerda ,&nbsp;Hugo Cogo-Moreira","doi":"10.1016/j.rpsm.2020.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0<!--> <!-->mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24<!--> <!-->h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.</p></div><div><h3>Results</h3><p>The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.</p></div><div><h3>Conclusions</h3><p>Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.</p></div>","PeriodicalId":21391,"journal":{"name":"Revista de psiquiatria y salud mental","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1888989120301178/pdfft?md5=8b99e6d2b06dcf3a387f454ce0eb0ade&pid=1-s2.0-S1888989120301178-main.pdf","citationCount":"2","resultStr":"{\"title\":\"The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression\",\"authors\":\"Victor Augusto Rodovalho Fava ,&nbsp;Luciana Maria Sarin ,&nbsp;Ana Cecília Lucchese ,&nbsp;Lorena Del Sant ,&nbsp;Eduardo Magalhães ,&nbsp;Rodrigo Simonini Delfino ,&nbsp;Marco Aurélio Tuena ,&nbsp;Carolina Nakahira ,&nbsp;Andrea Parolin Jackowski ,&nbsp;Guilherme Abdo ,&nbsp;Juliana Surjan ,&nbsp;Matheus Steiglich ,&nbsp;Matheus Ghossain Barbosa ,&nbsp;José Alberto Del Porto ,&nbsp;Acioly Luiz Tavares Lacerda ,&nbsp;Hugo Cogo-Moreira\",\"doi\":\"10.1016/j.rpsm.2020.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0<!--> <!-->mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24<!--> <!-->h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.</p></div><div><h3>Results</h3><p>The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.</p></div><div><h3>Conclusions</h3><p>Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.</p></div>\",\"PeriodicalId\":21391,\"journal\":{\"name\":\"Revista de psiquiatria y salud mental\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1888989120301178/pdfft?md5=8b99e6d2b06dcf3a387f454ce0eb0ade&pid=1-s2.0-S1888989120301178-main.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de psiquiatria y salud mental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1888989120301178\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de psiquiatria y salud mental","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1888989120301178","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 2

摘要

多剂量艾氯胺酮治疗单极和双相难治性抑郁症(TRD)有效。然而,在现实世界中,每次剂量后反应或不反应的概率仍然未知。本研究旨在评估通过皮下(SC)给药的四个剂量的艾氯胺酮。材料与方法我们对2017年4月至2018年12月期间在圣保罗联邦大学接受艾氯胺酮辅助项目治疗的70例TRD患者进行了回顾性分析。SC注射每周给药,剂量为0.5-1.0 mg/kg,与患者的精神药物联合使用。缓解被定义为蒙哥马利-Åsberg抑郁评定量表在基线和给药后24小时之间至少下降50%。我们使用隐马尔可夫模型来估计每次注射艾氯胺酮后的反应概率。结果SC注射艾氯胺酮后,“无应答者”变为“应答者”的概率为17.30%,保持“无应答者”的概率为82.70%。曾经是“应答者”的病人保持“应答者”身份的概率是95%。结论首次给药后无反应的TRD患者,经SC给药后仍有可能出现反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression

Introduction

The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC).

Material and methods

We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5–1.0 mg/kg, in conjunction with patients’ psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24 h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection.

Results

The probability of a patient that was a “non-responder” to become a “responder” following a SC injection of esketamine was 17.30% and the probability that this patient remains a “non-responder” was 82.70%. The probability of a patient that was a “responder” to remain as a “responder” was 95%.

Conclusions

Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
3.30%
发文量
58
期刊介绍: The Spanish Journal of Psychiatry and Mental Health (SJPMH), incorporated into ISSN 1888-9891, is the official scientific publication of the Spanish Society of Psychiatry and Mental Health. The journal focuses on studying mental illnesses, their pathological processes, and their psychosocial consequences, and aims to disseminate scientific advances in all areas related to mental health and illness. SJPMH accepts unpublished works on psychiatry and mental health, including their medical and social implications. The journal provides space for research in the biological, clinical, and psychosocial fields. Manuscripts undergo peer-review by external reviewers before being accepted for publication. SJPMH is indexed in Index Medicus/Medline, IBECS, Social Sciences Citation Index Journal Citation Reports/Social Sciences Edition, and Current Contents/Social and Behavioral Sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信